Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Events symbols : Atnm save search
Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial
Published: 2024-02-26 (Crawled : 16:00) - biospace.com/
ATNM | $6.67 -8.0% 1.2% 420K
|
Health Technology
|
| O: 2.04%
H: 19.98%
C: 18.71%
active aml trial
Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
Published: 2024-01-02 (Crawled : 13:30) - biospace.com/
ATNM | $6.67 -8.0% 1.2% 420K
|
Health Technology
|
| O: 1.77%
H: 5.42%
C: 2.9%
astct presentation therapy
Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition
Published: 2023-12-08 (Crawled : 21:00) - biospace.com/
ATNM | $6.67 -8.0% 1.2% 420K
|
Health Technology
|
| O: 0.94%
H: 1.68%
C: -0.56%
meeting leukemia potential
Actinium to Present Full Results from Pivotal Phase 3 Iomab-B SIERRA Trial on Investor Call Following the Late-Breaker Presentation at the 2023 Transplantation & Cellular Therapy Tandem Meetings on Saturday, February 18, 2023
Published: 2023-02-14 (Crawled : 16:00) - biospace.com/
ATNM | $6.67 -8.0% 1.2% 420K
|
Health Technology
|
| O: 1.77%
H: 3.17%
C: 1.44%
trial presentation therapy results
Actinium Announces Phase 3 Iomab-B SIERRA Data Accepted for Late-Breaker Presentation at the Transplantation & Cellular Therapy Tandem Meetings
Published: 2023-01-12 (Crawled : 14:20) - biospace.com/
ATNM | $6.67 -8.0% 1.2% 420K
|
Health Technology
|
| O: 2.34%
H: 7.02%
C: 1.09%
presentation therapy
Actinium to Present at the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference
Published: 2022-09-26 (Crawled : 12:00) - biospace.com/
ATNM | $6.67 -8.0% 1.2% 420K
|
Health Technology
|
| O: -2.74%
H: 8.45%
C: 2.82%
conference
Actinium Pharmaceuticals, Inc. Announces 72% MRD Negativity Rate in the Recently Completed Phase 1 Study of Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML
Published: 2021-12-14 (Crawled : 14:30) - biospace.com/
ATNM | $6.67 -8.0% 1.2% 420K
|
Health Technology
|
| O: -4.84%
H: 2.03%
C: -7.27%
als phase 1 aml
Actinium Pharmaceuticals, Inc. Reports 2 Remissions and 67% ORR in Patients with a TP53 Mutation in the Phase 1 portion of the Actimab-A Venetoclax Combination Trial in Patients with Relapsed or Refractory AML at the 63rd ASH Annual Meeting
Published: 2021-12-14 (Crawled : 13:30) - biospace.com/
ATNM | $6.67 -8.0% 1.2% 420K
|
Health Technology
|
| O: -4.84%
H: 2.03%
C: -7.27%
tp53 als trial phase 1 aml
Actinium Pharmaceuticals, Inc. Announces Pivotal Phase 3 SIERRA Trial at the 63rd ASH Annual Meeting
Published: 2021-12-13 (Crawled : 14:00) - biospace.com/
ATNM | $6.67 -8.0% 1.2% 420K
|
Health Technology
|
| O: 4.48%
H: 0.0%
C: 0.0%
als trial phase 3
Actinium Pharmaceuticals, Inc. Announces Participation in Two Panel Discussions at the 3rd Targeted Radiopharmaceuticals Summit
Published: 2021-12-08 (Crawled : 14:00) - biospace.com/
ATNM | $6.67 -8.0% 1.2% 420K
|
Health Technology
|
| O: 5.07%
H: 6.38%
C: 4.54%
Actinium Presents First Ever Data with a CD47 Immunotherapy in Combination with a HER2-Directed Targeted Radiotherapy in Solid Tumors at the Society for Immunotherapy for Cancer (SITC) Conference
Published: 2021-11-12 (Crawled : 14:00) - biospace.com/
ATNM | $6.67 -8.0% 1.2% 420K
|
Health Technology
|
| O: 2.08%
H: 0.0%
C: 0.0%
immunotherapy solid tumors therapy cancer iot conference her2+ her2- her2
Actinium Announces Expansion of R&D Team and Facilities to Accelerate Research Programs Focused on Solid Tumors and Novel Combinations with Checkpoint Inhibitors and Radioconjugates
Published: 2021-09-27 (Crawled : 14:00) - biospace.com/
ATNM | $6.67 -8.0% 1.2% 420K
|
Health Technology
|
| O: 11.98%
H: 2.5%
C: -3.4%
solid tumors expansion research
Actinium to Present at Four Upcoming Investor Conferences
Published: 2021-09-20 (Crawled : 13:00) - biospace.com/
ATNM | $6.67 -8.0% 1.2% 420K
|
Health Technology
|
| O: -4.21%
H: 3.98%
C: -1.33%
conference presentation
Actinium Announces Participation in H.C. Wainwright Global Life Sciences Conference
Published: 2021-03-02 (Crawled : 14:00) - biospace.com/
ATNM | $6.67 -8.0% 1.2% 420K
|
Health Technology
|
| O: -0.62%
H: 2.12%
C: 1.75%
life science conference
Actinium Announces Participation in BIO CEO & Investor Digital Conference
Published: 2021-02-10 (Crawled : 13:00) - biospace.com/
ATNM | $6.67 -8.0% 1.2% 420K
|
Health Technology
|
| O: 3.58%
H: 0.5%
C: -3.76%
ceo conference leo
Actinium to Participate in a Fireside Chat at the B. Riley Oncology Investor Conference
Published: 2021-01-20 (Crawled : 15:00) - biospace.com/
ATNM | $6.67 -8.0% 1.2% 420K
|
Health Technology
|
| O: 0.83%
H: 0.71%
C: -3.29%
Actinium Highlights Clinical Data to be Presented at the Upcoming 62nd American Society of Hematology Annual Meeting
Published: 2020-12-03 (Crawled : 19:00) - biospace.com/
ATNM | $6.67 -8.0% 1.2% 420K
|
Health Technology
|
| O: 2.9%
H: 0.56%
C: -2.35%
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.